Asan Medical center

Site:	Asan Medical center
Address:
City:	Seoul
State:	Songpa-gu
Zip:	138-736
Country:	Republic of Korea

26 trials at this site

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
	Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	Nilotinib	NCT00976612
1	Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors	Withdrawn	Not yet activated	Imatinib + Dovitinib	NCT02268435
1	A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors	Ongoing, but not recruiting	Closed	Cobimetinib + MPDL3280A	NCT01988896
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	A Study of NB003 in Patients With Advanced Malignancies	Active, not recruiting	Active	NB003	NCT04936178
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
2	REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response	Completed	Closed	Imatinib, Nilotinib
2	Dovitinib for Imatinib/Sunitinib-failed Gastrointestinal Stromal Tumors (GIST)	Completed	Active	Dovitinib	NCT01440959
2	Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation	Active, not recruiting	Closed	Imatinib	NCT01541709
2	A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs	Unknown	Active	Imatinib	NCT02712112
2	Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib	Completed	Closed	Regorafenib (BAY 73-4506)	NCT02889328
2	Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.	Recruiting	Active	Paclltaxel	NCT03944304
2	5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk	Recruiting	Active	Imatinib	NCT05385549
2	A Phase II Study of Oral Paclitaxel (Liporaxel) in GIST Patients With a Low P-glycoprotein Expression After Failure With Imatinib, Sunitinib and Regorafenib	Not yet recruiting	Not yet activated	Liporaxel	NCT06326346
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
2	The Efficacy and Safety of Temozolomide in SDH-deficient GIST (GIST)	Recruiting	Active	Temozolomide	NCT05661643
2	Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor	Recruiting	Active	Rivoceranib + Paclitaxel	NCT05905887
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
3	Rechallenge of Imatinib in GIST Having no Effective Treatment (RIGHT)	Completed	Closed	Imatinib	NCT01151852

Asan Medical center

26 trials at this site

Page 1 of 2 | Next | Last